
## Esther H Zhou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9387807/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications. Drug Safety, 2015, 38, 565-575.	1.4	31
2	Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. Pharmacoepidemiology and Drug Safety, 2017, 26, 712-721.	0.9	27
3	Long-Term Risk of Acute Myocardial Infarction, Stroke, and Death With Outpatient Use of Clarithromycin: A Retrospective Cohort Study. American Journal of Epidemiology, 2018, 187, 786-792.	1.6	27
4	Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study. Drug Safety, 2017, 40, 531-542.	1.4	21
5	Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis. JMIR Public Health and Surveillance, 2018, 4, e1.	1.2	21
6	Media Coverage of FDA Drug Safety Communications about Zolpidem: A Quantitative and Qualitative Analysis. Journal of Health Communication, 2017, 22, 365-372.	1.2	18
7	Changing patterns of asthma medication use related to US Food and Drug Administration long-acting β2-agonist regulation from 2005-2011. Journal of Allergy and Clinical Immunology, 2016, 137, 710-717.	1.5	17
8	Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem. Drug Safety, 2019, 42, 1287-1295.	1.4	13
9	Risk of acute myocardial infarction, stroke, or death in patients initiating olmesartan or other angiotensin receptor blockers — a cohort study using the Clinical Practice Research Datalink. Pharmacoepidemiology and Drug Safety, 2014, 23, 340-347.	0.9	12
10	Validity of <scp>ICDâ€10 M</scp> diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapies. Pharmacoepidemiology and Drug Safety, 2021, 30, 899-909.	0.9	11
11	Dosing Recommendations for Quetiapine When Coadministered With HIV Protease Inhibitors. Journal of Clinical Pharmacology, 2019, 59, 500-509.	1.0	10
12	Antidepressant medication dispensing among montelukast initiators. Journal of Asthma, 2013, 50, 990-995.	0.9	9
13	Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey. Journal of Law, Medicine and Ethics, 2019, 47, 430-441.	0.4	9
14	Use of Time-Dependent Propensity Scores to Adjust Hazard Ratio Estimates in Cohort Studies with Differential Depletion of Susceptibles. Epidemiology, 2020, 31, 82-89.	1.2	9
15	A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs. Drug Safety, 2021, 44, 743-751.	1.4	7
16	Characterization of Long-Acting Beta <sub>2</sub> -Adrenergic Agonists Utilization in Asthma Patients. Journal of Asthma, 2012, 49, 1079-1085.	0.9	6
17	The US Food and Drug Administration's drug safety recommendations and long-acting beta2-agonist dispensing pattern changes in adult asthma patients: 2003–2012. Journal of Asthma and Allergy, 2017, Volume10, 67-74.	1.5	5
18	Changes in emergency department visits for zolpidemâ€attributed adverse drug reactions after FDA Drug Safety Communications. Pharmacoepidemiology and Drug Safety, 2020, 29, 352-356.	0.9	4

Esther H Zhou

#	Article	IF	CITATIONS
19	Long-acting beta2-adrenergic agonist in pediatric and adolescent asthma patients, 2003–2011. Journal of Asthma, 2014, 51, 1061-1067.	0.9	3
20	The impact of FDA regulatory activities on incident dispensing of LABA-containing medication: 2005–2011. Journal of Asthma, 2018, 55, 907-914.	0.9	1
21	The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 700-709.	0.5	1
22	Trend changes of national zolpidem users and exposure cases after FDA drug safety communications. Pharmacoepidemiology and Drug Safety, 2021, 30, 1551-1559.	0.9	1